Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Catalyst gains on vigabatrin data

CPRX was up $0.33 (11%) to $3.25 on Friday after vigabatrin

Read the full 112 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE